Microcap Ledger Immix Biopharma, Inc. $IMMX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Los Angeles, CA
- Fiscal year end
- December 31
- Shares outstanding
- 71,539,314 [10-Q 2026-08-07]
What the company doesAI summary of filing
Immix Biopharma is a clinical-stage biopharmaceutical company developing chimeric antigen receptor T-cell (CAR-T) therapies, with its lead candidate NXC-201 currently in a Phase 1b/2 clinical trial for relapsed/refractory light chain (AL) amyloidosis. The company generates no revenue and is pre-commercial, relying on capital raises and grant funding to support clinical development. NXC-201 has received FDA Breakthrough Therapy, RMAT, and Orphan Drug designations, with positive interim Phase 2 data showing a 75% complete response rate as of November 2025. The company is developing its therapies using its proprietary N-GENIUS platform and intends to seek regulatory approval through a Biologics License Application submission following final trial readout. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$21.64M | −$21.56M | $225.49M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | — | −$29.40M | −$23.93M | $93.93M | [10-Q 2026-08-07] |
| FY ended Dec 2024 | — | −$21.61M | −$14.60M | $17.68M | [10-K/A 2026-03-27] |
- Quarterly cash burn
- −$10.78M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 27,507,637 | [10-Q 2024-11-12] |
| 2025-03-11 | 27,722,108 | [10-K/A 2025-05-19] |
| 2025-05-06 | 27,877,293 | [10-Q/A 2025-05-19] |
| 2025-08-01 | 28,834,111 | [10-Q 2025-08-08] |
| 2025-11-05 | 33,577,873 | [10-Q 2025-11-07] |
| 2026-03-20 | 52,964,549 | [10-K/A 2026-03-27] |
| 2026-04-30 | 54,411,427 | [10-Q 2026-05-07] |
| 2026-08-03 | 71,539,314 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-01-09; declared effective 2026-01-22 [S-3 2026-01-09]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-22 | Adams Helen C. | grant | 6,250 | — | [4 2026-05-29] |
| 2026-05-22 | Ng Carey | grant | 6,250 | — | [4 2026-05-29] |
| 2026-05-22 | Marquet Magda | grant | 6,250 | — | [4 2026-05-29] |
| 2026-05-22 | Chang Nancy T | grant | 6,250 | — | [4 2026-05-29] |
| 2026-05-22 | Chudnovsky Yekaterina | grant | 6,250 | — | [4 2026-05-29] |
| 2026-05-22 | Hsu Jason | grant | 6,250 | — | [4 2026-05-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Other events |
| 2026-09-29 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-29 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-07-20 | 8-K | Other events |
| 2026-06-05 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-29 | 8-K | Shareholder vote results |
| 2026-05-21 | 8-K | Other events |
| 2026-05-21 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-21 | 8-K | Regulation FD disclosure; Other events |
Alerts for $IMMX
Email me when Immix Biopharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.